 high-dos medroxyprogesteron acet versu estramustin therapy-resist prostat cancer randomis studi seri patient metastat prostat cancer first-lin hormon treatment high-dos medroxyprogesteron acet mpa mg i.m daili day mg weekli patient mg os patient treatment side effect evalu mpa-treat patient evalu estramustine-tr patient progression-fre surviv short group signific differ year patient signific differ treatment cumul observ surviv rate spcg criteria remiss week mpa-treat patient estramustine-tr patient differ signific cross-ov patient mpa group remiss estramustin group respons rate subject object respons criteria mpa side effect